Page last updated: 2024-10-17

bupropion and Lassitude

bupropion has been researched along with Lassitude in 21 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions."9.41Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023)
"A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue."9.34A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020)
"Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD)."9.19Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. ( Cooper, JA; Papakostas, GI; Tucker, VL, 2014)
"This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life."9.12An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006)
"Improvement of fatigue in patients with multiple sclerosis (MS) who were given bupropion has been previously reported, but scales for lethargy and depression were not used."7.76Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. ( De Sarro, G; Gallelli, L; Loiacono, D; Siniscalchi, A; Tolotta, GA, 2010)
"To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients."7.72Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004)
"Bupropion was administered 75 mg twice daily for twelve weeks."7.30The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial. ( Azizi, H; Baghbanian, SM; Bakhshi, A; Ghazaeian, M; Khalili, B, 2023)
"Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6."6.94Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020)
"Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants."6.44Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. ( Han, C; Lee, C; Lim, HK; Masand, PS; Pae, CU; Patkar, AA; Steffens, DC, 2007)
"This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions."5.41Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023)
"A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue."5.34A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020)
"Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD)."5.19Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. ( Cooper, JA; Papakostas, GI; Tucker, VL, 2014)
"This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life."5.12An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006)
"Intensive longitudinal data from a randomized placebo-controlled smoking cessation trial (N=1504) are used to estimate a dynamical model of withdrawal-related processes including momentary craving, negative affect, quitting self-efficacy, and cessation fatigue for each of six treatment conditions (nicotine patch, nicotine lozenge, bupropion, patch + lozenge, bupropion + lozenge, and placebo)."3.85Evaluating the effect of smoking cessation treatment on a complex dynamical system. ( Bekiroglu, K; Lagoa, CM; Lanza, ST; Piper, ME; Russell, MA, 2017)
"Improvement of fatigue in patients with multiple sclerosis (MS) who were given bupropion has been previously reported, but scales for lethargy and depression were not used."3.76Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. ( De Sarro, G; Gallelli, L; Loiacono, D; Siniscalchi, A; Tolotta, GA, 2010)
"To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients."3.72Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004)
"Bupropion was administered 75 mg twice daily for twelve weeks."3.30The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial. ( Azizi, H; Baghbanian, SM; Bakhshi, A; Ghazaeian, M; Khalili, B, 2023)
"Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6."2.94Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020)
"Exercise fatigue was associated with an 8 ± 11% reduction in the peak velocity of prosaccades, and a 10 ± 11% decrement in antisaccade peak velocity."2.84Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition. ( Connell, CJ; Gant, N; Srzich, A; Thompson, B; Turuwhenua, J, 2017)
"Bupropion XL was superior to placebo at endpoint in reducing the IDS-IVR-30 total score (p = ."2.72Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. ( Hampton, KD; Jefferson, JW; Krishen, A; Modell, JG; Nelson, JC; Rush, AJ; VanMeter, SA; Wightman, DS, 2006)
"Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants."2.44Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. ( Han, C; Lee, C; Lim, HK; Masand, PS; Pae, CU; Patkar, AA; Steffens, DC, 2007)
"Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD)."2.43Symptoms of fatigue and sleepiness in major depressive disorder. ( Baldwin, DS; Papakostas, GI, 2006)
"Fatigue was assessed with the Modified Fatigue Impact Scale (MFIS)."1.39Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013)
" No clinically significant bupropion-related changes in blood pressure, pulse rates, respiration rate, body temperature, or laboratory parameters were recorded; only 41 patients were discontinued due to intolerance to adverse experiences."1.27Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. ( Harto-Truax, N; Kirksey, DF, 1983)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.76)18.7374
1990's0 (0.00)18.2507
2000's7 (33.33)29.6817
2010's8 (38.10)24.3611
2020's5 (23.81)2.80

Authors

AuthorsStudies
Correa-Morales, JE1
Cuellar-Valencia, L1
Mantilla-Manosalva, N1
Quintero-Muñoz, E1
Iriarte-Aristizábal, MF1
Giraldo-Moreno, S1
Rodríguez-Campos, LF1
Baghbanian, SM3
Khalili, B3
Bakhshi, A3
Azizi, H3
Ghazaeian, M3
Salehifar, E1
Azimi, S1
Janbabai, G1
Zaboli, E1
Hendouei, N1
Saghafi, F1
Borhani, S1
Jim, HSL1
Hoogland, AI1
Han, HS1
Culakova, E1
Heckler, C1
Janelsins, M1
Williams, GC1
Bower, J1
Cole, S1
Desta, Z1
Babilonia, MB1
Morrow, G1
Peppone, L1
Hashash, JG1
Knisely, MR1
Germain, A1
McAuliff, K1
Strassburger, M1
Vachon, A1
Binion, DG1
Regueiro, M1
Wallace, M1
Szigethy, E1
Bekiroglu, K1
Russell, MA1
Lagoa, CM1
Lanza, ST1
Piper, ME1
Ashrafi, F1
Mousavi, S1
Karimi, M1
Kojima, G1
Tamai, A1
Karino, S1
Yuasa, M1
Epure, J1
Tsuzaki, B1
Tanabe, M1
Barsevick, AM1
Irwin, MR1
Hinds, P1
Miller, A1
Berger, A1
Jacobsen, P1
Ancoli-Israel, S1
Reeve, BB1
Mustian, K1
O'Mara, A1
Lai, JS1
Fisch, M1
Cella, D1
Cooper, JA1
Tucker, VL1
Papakostas, GI2
Connell, CJ1
Thompson, B1
Turuwhenua, J1
Srzich, A1
Gant, N1
Siniscalchi, A1
Gallelli, L1
Tolotta, GA1
Loiacono, D1
De Sarro, G1
Pardini, M1
Capello, E1
Krueger, F1
Mancardi, G1
Uccelli, A1
Paul, MA1
Gray, G1
Kenny, G1
Lange, M1
Cullum, JL1
Wojciechowski, AE1
Pelletier, G2
Simpson, JS2
Moss, EL1
Forsyth, P1
Jefferson, JW1
Rush, AJ1
Nelson, JC1
VanMeter, SA1
Krishen, A1
Hampton, KD1
Wightman, DS1
Modell, JG1
Baldwin, DS1
Pae, CU1
Lim, HK1
Han, C1
Patkar, AA1
Steffens, DC1
Masand, PS1
Lee, C1
Hasegawa, H1
Piacentini, MF1
Sarre, S1
Michotte, Y1
Ishiwata, T1
Meeusen, R1
Kirksey, DF1
Harto-Truax, N1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306]60 participants (Anticipated)Interventional2023-05-17Recruiting
Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329]80 participants (Anticipated)Interventional2018-05-13Recruiting
An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms[NCT00064467]Phase 3268 participants Interventional2003-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for bupropion and Lassitude

ArticleYear
Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review.
    Journal of pain and symptom management, 2023, Volume: 65, Issue:1

    Topics: Adult; Bupropion; Fatigue; Humans; Neoplasms

2023
Symptoms of fatigue and sleepiness in major depressive disorder.
    The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 6

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Bupropion; Ce

2006
Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
    Expert review of neurotherapeutics, 2007, Volume: 7, Issue:10

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Fatigue; Humans

2007

Trials

9 trials available for bupropion and Lassitude

ArticleYear
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial.
    Multiple sclerosis and related disorders, 2023, Volume: 69

    Topics: Bupropion; Double-Blind Method; Fatigue; Female; Humans; Multiple Sclerosis; Quality of Life; Sexual

2023
Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial.
    BMC cancer, 2020, Feb-27, Volume: 20, Issue:1

    Topics: Adult; Aged; Bupropion; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S

2020
A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.
    Contemporary clinical trials, 2020, Volume: 91

    Topics: Age Factors; Antidepressive Agents, Second-Generation; Breast Neoplasms; Bupropion; Cancer Survivors

2020
Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Behavior Therapy; Bupropion; Crohn Disease; Fatigue; Female; Humans; Quality of L

2022
Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.
    Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Double-Blind

2014
Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition.
    Scientific reports, 2017, 02-15, Volume: 7

    Topics: Adult; Bupropion; Caffeine; Central Nervous System Stimulants; Dopamine Uptake Inhibitors; Fatigue;

2017
The impact of bupropion on psychomotor performance.
    Aviation, space, and environmental medicine, 2002, Volume: 73, Issue:11

    Topics: Adult; Aerospace Medicine; Antidepressive Agents, Second-Generation; Bupropion; Cross-Over Studies;

2002
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
    Psycho-oncology, 2006, Volume: 15, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Delayed-Action Preparati

2006
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:6

    Topics: 4-Aminopyridine; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depressi

2006

Other Studies

9 other studies available for bupropion and Lassitude

ArticleYear
Evaluating the effect of smoking cessation treatment on a complex dynamical system.
    Drug and alcohol dependence, 2017, 11-01, Volume: 180

    Topics: Bupropion; Craving; Drug Therapy, Combination; Fatigue; Humans; Nicotine; Smoking Cessation; Substan

2017
Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
    Asian Pacific journal of cancer prevention : APJCP, 2018, Jun-25, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action

2018
Bupropion-related visual hallucinations in a veteran with posttraumatic stress disorder and multiple sclerosis.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:5

    Topics: Aged, 80 and over; Bupropion; Dopamine Uptake Inhibitors; Fatigue; Hallucinations; Humans; Male; Mul

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis.
    Clinical therapeutics, 2010, Volume: 32, Issue:12

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Fatigue; Female; Humans; Middle Aged; Multiple

2010
Reward responsiveness and fatigue in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:2

    Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso

2013
Bupropion sustained release treatment reduces fatigue in cancer patients.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:2

    Topics: Adjustment Disorders; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiet

2004
Influence of brain catecholamines on the development of fatigue in exercising rats in the heat.
    The Journal of physiology, 2008, Jan-01, Volume: 586, Issue:1

    Topics: Animals; Body Temperature Regulation; Brain; Bupropion; Catecholamines; Dopamine; Dopamine Uptake In

2008
Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Depressive Disorder; Dru

1983